Get the Stockscreener App
6.86
0.44%
-0.03
After Hours:
6.92
0.06
+0.87%
Verastem Inc stock is traded at $6.86, with a volume of 1.17M.
It is down -0.44% in the last 24 hours and up +13.39% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$6.89
Open:
$6.9
24h Volume:
1.17M
Relative Volume:
0.47
Market Cap:
$621.27M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-2.0614
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
-4.46%
1M Performance:
+13.39%
6M Performance:
+16.27%
1Y Performance:
-24.45%
1-Day Range:
$6.62
$6.955
1-Week Range:
$6.62
$7.86
52-Week Range:
$3.43
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.86 | 617.64M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Verastem (NASDAQ:VSTM) Shares Down 8.6%Should You Sell? - MarketBeat
Verastem (VSTM) Q2 2026 Earnings Call Transcript - AOL.com
VSTM | Verastem, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Verastem (NASDAQ:VSTM) Shares Up 6.4%What's Next? - MarketBeat
Precision Trading with Verastem Inc. (VSTM) Risk Zones - Stock Traders Daily
Verastem (VSTM) Slips 1.35% to $6.58 as Biotech Stock Holds Above Key SupportDebt Free Companies - vinanet.vn
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Verastem (VSTM) Pulls Back 1.42% to $6.58 as Support HoldsOBV Breakout - vinanet.vn
Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital - Stock Titan
Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM - MarketBeat
Verastem Inc (VSTM) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
VSTM Maintains by Mizuho -- Price Target Lowered to $13.00 - GuruFocus
Mizuho lowers Verastem stock price target on valuation to $13 By Investing.com - Investing.com Nigeria
Mizuho lowers Verastem stock price target on valuation to $13 - Investing.com India
Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating - Yahoo Finance
Q2 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Q1 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Weekly Recap: Q2 2026 revenue, cash, losses and RAMP Phase 3 readout - TradingView
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $12 to $18 - Moomoo
Verastem (VSTM) Stock Rallies On Revenue Surge And Pipeline Pressure - Sahm
Verastem Inc (VSTM) Stock News Today - TradingKey
Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Verastem Q2 Earnings Call Highlights - MarketBeat
VSTM Maintained by Guggenheim -- Price Target Lowered to $12.00 - GuruFocus
Verastem Oncology (VSTM) Posts Solid Q2 2026; Market Pricing Ref - GuruFocus
State Street Corporation (VSTM) discloses 5.8% beneficial ownership in INC common stock - Stock Titan
Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Verastem, Inc. Stock 12‑Month Price Target Cut to $14.88, Implies 152% Upside - TradingView
VerastemEnters Amendment No. 3 To Note Purchase Agreement On August 6, 2026SEC Filing - TradingView
Verastem Amends Oberland Financing, Adding Up to $75 Million Revenue-Share Notes Maturing 2033 - TradingView
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong R - GuruFocus
Verastem, Inc. (VSTM) Stock Analysis: 151.69% Potential Upside In Biotech Space - DirectorsTalk Interviews
How Did Verastem Inc (VSTM) Perform in Q2 2026? Revenue of $40.1 - GuruFocus
Earnings call transcript: Verastem beats Q2 2026 estimates, shares jump after hours - Investing.com
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verastem, Inc. 2026: Revenue $40.08M, EPS ($0.35) — 10-Q Summary - TradingView
VERASTEM ($VSTM) Releases Q2 2026 Earnings - Moomoo
Verastem: Q2 Earnings Snapshot - Barchart.com
Verastem (Nasdaq: VSTM) lifts Q2 2026 revenue to $40M, discloses going‑concern risk - Stock Titan
Verastem Q2 revenue jumps on new product sales and milestone - TradingView
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - Yahoo Finance
Verastem Inc (VSTM) President and CEO Dan Paterson Sells 1,302 S - GuruFocus
BlackRock, Inc. Trims Verastem Inc (VSTM) Stake in Recent 13DG F - GuruFocus
Verastem, Inc. (VSTM) CEO sells 1,302 shares to cover RSU taxes - Stock Titan
VSTM|Verastem Inc|Price:5.695|Chg%:-0.105 - TradingKey
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):